Current therapeutic strategies for recurrent hepatitis B virus infection after liver transplantation

Table 2 Use of ADV in treatment of recurrent graft infection after LT

Author (Ref.)	n	Pre-treatment		Treatment duration (mo), mean (range)	ADV dosage (mg/d)	ConcurrentLAM use	Post-treatment
		HBV DNA+ (%)	HBeAg+ (%)				HBV DNA negative following treatment (%)	HBsAg seroconversion (%)	ALT normalization (%)	Development of ADV mutants
Akyildiz et al[44]	11	81.8	9.1	18 (6-48)	10	Yes	77.8	11.1	81.8	None
Limquiaco et al[45]	7	100	71.4	35 (22-48)	10	Yes	28.6	20	86	None
Bárcena et al[46]	42	100	71.4	21.5 (12-31)	10	No	64	20	70.5	None
Herreros de Tejada Echanojáuregui et al[47]	7	100	71.4	11	10	Yes1	42.9	20	NA	None
Neff et al[48]	9	100	77.8	30 (6-48)	10	No	0	57.1	NA	None

¹LAM was changed to ADV in 5 patients and ADV was added to LAM in the other 2 patients. ADV: Adefovir dipivoxil.